Pages

Friday, May 25, 2012

Abbott To Purchase Experimental Kidney Treatment From Action Pharma.

The AP Share to FacebookShare to Twitter (5/4) reports, "Abbott Laboratories will spend $110 million to buy a potential kidney treatment from the privately held Danish company Action Pharma, the company said Thursday. The drug, labeled AP214, is in mid-stage clinical testing and is designed to prevent acute kidney injury in patients undergoing major cardiac surgery," by reducing "systemic inflammation and cellular death caused by a lack of blood flow."

No comments:

Post a Comment